Treatment of non-small-cell lung cancer and pharmacogenomics: Where we are and where we are going

Rafael Rosell, Mauricio Cuello, Fabiana Cecere, Mariacarmela Santarpia, Noemi Reguart, Enriqueta Felip, Miquel Taron

Research output: Contribution to journalArticle

Abstract

Purpose of review: This review highlights the numerous molecular biology findings in the field of lung cancer with potential therapeutic impact in both the near and distant future. Recent findings: Abundant preclinical and clinical data indicate that BRCA1 mRNA expression is a differential modulator of chemotherapy sensitivity. Single nucleotide polymorphisms in the excision repair cross-complementing 1 gene (ERCC1) influence survival with cisplatin-based chemotherapy. For the first time, epidermal growth factor receptor (EGFR) mutations have been shown to predict dramatic responses in metastatic lung adenocarcinomas. The crosstalk between estrogen and EGFR pathways have also been revealed. MicroRNAs control the expression of cognate target genes and predict relapse in surgically resected non-small-cell lung cancer patients. Overexpression of the Wingless-type (Wnt) genes and methylation of Wnt antagonists have been documented in non-small-cell lung cancer. Summary: Understanding the relevance of these findings can help to change the clinical practice in oncology towards customizing chemotherapy and targeted therapies, leading to improvement both in survival and in cost-effectiveness.

Original languageEnglish
Pages (from-to)135-143
Number of pages9
JournalCurrent Opinion in Oncology
Volume18
Issue number2
DOIs
Publication statusPublished - Mar 2006

Fingerprint

Pharmacogenetics
Non-Small Cell Lung Carcinoma
Epidermal Growth Factor Receptor
Drug Therapy
Genes
Survival
MicroRNAs
DNA Repair
Methylation
Cisplatin
Cost-Benefit Analysis
Single Nucleotide Polymorphism
Molecular Biology
Lung Neoplasms
Estrogens
Therapeutics
Recurrence
Messenger RNA
Mutation

Keywords

  • Acquired resistance to tyrosine kinase inhibitors
  • BRCA1 mRNA
  • EGFR tyrosine kinase mutations
  • Erythropoietin receptor
  • Estrogen receptors
  • K-ras mutations
  • microRNAs
  • Single nucleotide polymorphisms
  • Wnt

ASJC Scopus subject areas

  • Cancer Research

Cite this

Treatment of non-small-cell lung cancer and pharmacogenomics : Where we are and where we are going. / Rosell, Rafael; Cuello, Mauricio; Cecere, Fabiana; Santarpia, Mariacarmela; Reguart, Noemi; Felip, Enriqueta; Taron, Miquel.

In: Current Opinion in Oncology, Vol. 18, No. 2, 03.2006, p. 135-143.

Research output: Contribution to journalArticle

Rosell, R, Cuello, M, Cecere, F, Santarpia, M, Reguart, N, Felip, E & Taron, M 2006, 'Treatment of non-small-cell lung cancer and pharmacogenomics: Where we are and where we are going', Current Opinion in Oncology, vol. 18, no. 2, pp. 135-143. https://doi.org/10.1097/01.cco.0000208786.91947.eb
Rosell, Rafael ; Cuello, Mauricio ; Cecere, Fabiana ; Santarpia, Mariacarmela ; Reguart, Noemi ; Felip, Enriqueta ; Taron, Miquel. / Treatment of non-small-cell lung cancer and pharmacogenomics : Where we are and where we are going. In: Current Opinion in Oncology. 2006 ; Vol. 18, No. 2. pp. 135-143.
@article{70c72da81f2a41f5b59c22f049ce7bbf,
title = "Treatment of non-small-cell lung cancer and pharmacogenomics: Where we are and where we are going",
abstract = "Purpose of review: This review highlights the numerous molecular biology findings in the field of lung cancer with potential therapeutic impact in both the near and distant future. Recent findings: Abundant preclinical and clinical data indicate that BRCA1 mRNA expression is a differential modulator of chemotherapy sensitivity. Single nucleotide polymorphisms in the excision repair cross-complementing 1 gene (ERCC1) influence survival with cisplatin-based chemotherapy. For the first time, epidermal growth factor receptor (EGFR) mutations have been shown to predict dramatic responses in metastatic lung adenocarcinomas. The crosstalk between estrogen and EGFR pathways have also been revealed. MicroRNAs control the expression of cognate target genes and predict relapse in surgically resected non-small-cell lung cancer patients. Overexpression of the Wingless-type (Wnt) genes and methylation of Wnt antagonists have been documented in non-small-cell lung cancer. Summary: Understanding the relevance of these findings can help to change the clinical practice in oncology towards customizing chemotherapy and targeted therapies, leading to improvement both in survival and in cost-effectiveness.",
keywords = "Acquired resistance to tyrosine kinase inhibitors, BRCA1 mRNA, EGFR tyrosine kinase mutations, Erythropoietin receptor, Estrogen receptors, K-ras mutations, microRNAs, Single nucleotide polymorphisms, Wnt",
author = "Rafael Rosell and Mauricio Cuello and Fabiana Cecere and Mariacarmela Santarpia and Noemi Reguart and Enriqueta Felip and Miquel Taron",
year = "2006",
month = "3",
doi = "10.1097/01.cco.0000208786.91947.eb",
language = "English",
volume = "18",
pages = "135--143",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Treatment of non-small-cell lung cancer and pharmacogenomics

T2 - Where we are and where we are going

AU - Rosell, Rafael

AU - Cuello, Mauricio

AU - Cecere, Fabiana

AU - Santarpia, Mariacarmela

AU - Reguart, Noemi

AU - Felip, Enriqueta

AU - Taron, Miquel

PY - 2006/3

Y1 - 2006/3

N2 - Purpose of review: This review highlights the numerous molecular biology findings in the field of lung cancer with potential therapeutic impact in both the near and distant future. Recent findings: Abundant preclinical and clinical data indicate that BRCA1 mRNA expression is a differential modulator of chemotherapy sensitivity. Single nucleotide polymorphisms in the excision repair cross-complementing 1 gene (ERCC1) influence survival with cisplatin-based chemotherapy. For the first time, epidermal growth factor receptor (EGFR) mutations have been shown to predict dramatic responses in metastatic lung adenocarcinomas. The crosstalk between estrogen and EGFR pathways have also been revealed. MicroRNAs control the expression of cognate target genes and predict relapse in surgically resected non-small-cell lung cancer patients. Overexpression of the Wingless-type (Wnt) genes and methylation of Wnt antagonists have been documented in non-small-cell lung cancer. Summary: Understanding the relevance of these findings can help to change the clinical practice in oncology towards customizing chemotherapy and targeted therapies, leading to improvement both in survival and in cost-effectiveness.

AB - Purpose of review: This review highlights the numerous molecular biology findings in the field of lung cancer with potential therapeutic impact in both the near and distant future. Recent findings: Abundant preclinical and clinical data indicate that BRCA1 mRNA expression is a differential modulator of chemotherapy sensitivity. Single nucleotide polymorphisms in the excision repair cross-complementing 1 gene (ERCC1) influence survival with cisplatin-based chemotherapy. For the first time, epidermal growth factor receptor (EGFR) mutations have been shown to predict dramatic responses in metastatic lung adenocarcinomas. The crosstalk between estrogen and EGFR pathways have also been revealed. MicroRNAs control the expression of cognate target genes and predict relapse in surgically resected non-small-cell lung cancer patients. Overexpression of the Wingless-type (Wnt) genes and methylation of Wnt antagonists have been documented in non-small-cell lung cancer. Summary: Understanding the relevance of these findings can help to change the clinical practice in oncology towards customizing chemotherapy and targeted therapies, leading to improvement both in survival and in cost-effectiveness.

KW - Acquired resistance to tyrosine kinase inhibitors

KW - BRCA1 mRNA

KW - EGFR tyrosine kinase mutations

KW - Erythropoietin receptor

KW - Estrogen receptors

KW - K-ras mutations

KW - microRNAs

KW - Single nucleotide polymorphisms

KW - Wnt

UR - http://www.scopus.com/inward/record.url?scp=33646684694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646684694&partnerID=8YFLogxK

U2 - 10.1097/01.cco.0000208786.91947.eb

DO - 10.1097/01.cco.0000208786.91947.eb

M3 - Article

C2 - 16462182

AN - SCOPUS:33646684694

VL - 18

SP - 135

EP - 143

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 2

ER -